Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New study aims to spot hidden heart attack risks with High-Tech imaging

NCT ID NCT07548554

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at 40 people who recently had a heart attack and had one blockage treated. Researchers will use special pressure wires and optical imaging to examine other blockages that were not treated. The goal is to see how many of these leftover blockages are actually dangerous and might need treatment to prevent another heart attack.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to better ways to identify which non-culprit blockages are dangerous and need treatment, potentially preventing future heart attacks.
What could go wrong
This is a small, early-stage study with only 40 participants, so results may not apply to everyone. The tests are complex and not yet standard practice, so benefits are uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2026

Expected to finish

Apr 2027

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients presented with acute coronary syndrome undergoing successful PCI for the culprit vessel and at least one additional non-culprit vessel were enrolled form the Mehmet Akif Ersoy Hospital Emergency Department

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Presenting to the clinic with a diagnosis of Acute Coronary Syndrome. * Having a significant (total or subtotal) culprit lesion detected during the index angiography procedure and having successfully undergone percutaneous coronary intervention (PCI) for this lesion. * Having at least one distant non-culprit lesion with moderate stenosis (between 50% and 90%) according to visual angiographic evaluation in coronary arteries (or side branches with a diameter \>2.5 mm) that are not major epicardial and not major left main coronary arteries. * Having TIMI III flow in the vessel containing the non-culprit lesion to be evaluated. * The patient being able to understand the nature of the study and signing the written informed consent form. * Patients for whom intracoronary hemodynamic evaluation is planned for treatment planning of the non-culprit lesion after the index procedure. Exclusion Criteria: Clinical Exclusion Criteria: * Advanced renal insufficiency to the extent that the patient cannot tolerate the additional contrast load required for intracoronary imaging (IC-OCT) (e.g., eGFR \< 30 mL/min/1.73 m²). * Known serious allergy or absolute contraindication to the hyperemic agents to be used (e.g., adenosine, papaverine), iodinated contrast agents, or mandatory antiplatelet/anticoagulant therapy. * Patients presenting to the hospital due to heart failure and cardiogenic shock. * Additional investigation required due to in-stent restenosis of a non-culprit vessel. * Patients with blood disorders, bleeding disorders, cancer, end-stage liver or kidney failure, patients with active bleeding, and pregnant women. Angiographic and Procedural Exclusion Criteria: * Presence of significant stenosis in the left main coronary artery (LMCA) or the patient having previously undergone coronary artery bypass graft (CABG) surgery. * Failure of PCI on the culprit lesion in the index procedure, no-reflow, etc. The vessel containing the non-culprit lesion has technical impediments that prevent safe passage of the IC-OCT catheter or pressure/flow wire (e.g., excessive tortuosity, advanced angulation, very dense calcification, or chronic total occlusion \[CTO\]).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute coronary syndromes (ACS) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Istanbul Mehmet Akif Ersoy Training and Research Hospital

    Istanbul, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.